Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients

Inclusion Criteria: * Documented HIV infection prior to study entry * Must be willing to comply with study-mandated evaluations; including not changing their antiretroviral regimen (unless medically indicated) during the study period. Cohort 1, 2 and 3 (Enrollment Completed) Cohort 5: * Must have received HAART therapy, and had undetectable viral loads for at least 1 year. * HIV-1 RNA \< 50 copies/mL obtained within 60 days prior to study entry performed with an ultrasensitive HIV-1 PCR assay. * CD4+ T cell count \>500 cells/mm3 * Heterozygous for the CCR5 delta-32 mutation * On stable antiretroviral medication (no changes to treatment within 4 weeks of screening and willing to discontinue current antiretroviral therapy during the structured therapy interruption Cohort 4 * On stable antiretroviral medication (no changes to treatment within 4 weeks of screening and willing to continue on current antiretroviral therapy through week 8 after infusion * CD4+ T cell count \>350 cells/mm3. * HIV-1 \>1,000 copies/mL at screen and not responding to current antiviral therapy (i.e. HIV-RNA plasma levels \> 1000 copies/ml after at least 12 weeks of stable, unchanged ARV therapy). Exclusion Criteria: * Acute or chronic hepatitis B or hepatitis C infection * Active or recent (in prior 6 months) AIDS defining complication. * Any cancer or malignancy within the past 5 years, with the exception of successfully treated basal cell or squamous cell carcinoma of the skin or low grade (0 or 1) anal or cervical dysplasia. * Current diagnosis of NYHA grade 3 or 4 CHF, uncontrolled angina or uncontrolled arrhythmias. * History or any features on physical examination indicative of a bleeding diathesis. * Previous treatment with any HIV experimental vaccine within 6 months prior to screening, or any previous gene therapy using an integrating vector. * Use of chronic corticosteroids, hydroxyurea, or immunomodulating agents (e.g., interleukin-2, interferon-alpha or gamma, granulocyte colony stimulating factors, etc.) within 30 days prior to enrollment * Breast-feeding, pregnant or unwilling to use acceptable methods of birth control for 6 months following the last infusion of SB-728-T cells. * warfarin or any other medication that is likely to affect platelet function or other aspects of blood coagulation during the 2 week period prior to leukapheresis. * Active drug or alcohol use or dependence * Serious illness requiring systemic treatment and/or hospitalization within 30 days prior to study entry. * Recent vaccination or intercurrent illness (within 5 weeks prior to infusion) * Have an allergy or hypersensitivity to study product excipients (human serum albumin, DMSO and Dextran 40). * Subjects who are currently taking maraviroc or have received maraviroc within 6 months prior to screening. Cohort 4 only: * HIV-1 RNA \>1,000 copies/mL at screen and not responding to current antiviral therapy * CD4+ T cell count \>350 cells/mm3